Business Description
Kane Biotech Inc
NAICS : 325410
SIC : 3741
ISIN : CA4838092084
Description
Kane Biotech Inc is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The company has a portfolio of biotechnologies, intellectual property and products developed by its own biofilm research expertise and acquired from research institutions. The company's operating segments are animal health and human health. It derives maximum revenue from Animal health segment.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.21 | |||||
Equity-to-Asset | -0.78 | |||||
Debt-to-Equity | -1.35 | |||||
Debt-to-EBITDA | -0.99 | |||||
Piotroski F-Score | 1/9 | |||||
Altman Z-Score | -33 | |||||
Beneish M-Score | -1.77 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 44.2 | |||||
3-Year EBITDA Growth Rate | 14.5 | |||||
3-Year EPS without NRI Growth Rate | 16.2 | |||||
3-Year FCF Growth Rate | 6.9 | |||||
3-Year Book Growth Rate | 57.5 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 43.56 | |||||
9-Day RSI | 44 | |||||
14-Day RSI | 43.22 | |||||
3-1 Month Momentum % | -14.29 | |||||
6-1 Month Momentum % | -25 | |||||
12-1 Month Momentum % | -25 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.45 | |||||
Quick Ratio | 0.27 | |||||
Cash Ratio | 0.15 | |||||
Days Inventory | 1261.16 | |||||
Days Sales Outstanding | 489.6 | |||||
Days Payable | 3368.43 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -13.3 | |||||
Shareholder Yield % | -35.63 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | -81.03 | |||||
Operating Margin % | -3732.76 | |||||
Net Margin % | -3824.14 | |||||
EBITDA Margin % | -3348.28 | |||||
FCF Margin % | -4705.17 | |||||
OCF Margin % | -4548.28 | |||||
ROA % | -80.05 | |||||
ROIC % | -107.24 | |||||
3-Year ROIIC % | -19.95 | |||||
ROC (Joel Greenblatt) % | -368 | |||||
ROCE % | -396.83 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 8.33 | |||||
EV-to-EBIT | -3.2 | |||||
EV-to-EBITDA | -3.42 | |||||
EV-to-Revenue | 114.64 | |||||
EV-to-FCF | -2.44 | |||||
Earnings Yield (Greenblatt) % | -31.25 | |||||
FCF Yield % | -53.24 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Kane Biotech Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil C$) | 0.058 | ||
| EPS (TTM) (C$) | -0.003 | ||
| Beta | 1.0604 | ||
| 3-Year Sharpe Ratio | -0.5 | ||
| 3-Year Sortino Ratio | -0.64 | ||
| Volatility % | 57 | ||
| 14-Day RSI | 43.22 | ||
| 14-Day ATR (C$) | 0.001737 | ||
| 20-Day SMA (C$) | 0.02625 | ||
| 12-1 Month Momentum % | -25 | ||
| 52-Week Range (C$) | 0.02 - 0.05 | ||
| Shares Outstanding (Mil) | 205.06 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Kane Biotech Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Kane Biotech Inc Stock Events
| Event | Date | Price (C$) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-27 | In 116 days | ||
| Second quarter earnings results for 2026 | 2026-08-28 | In 25 days | ||
| General meeting for 2026 | 2026-06-24 16:00 | 0.03 (+20.00%) | ||
| First quarter earnings results for 2026 | 2026-05-28 | 0.04 (+0.00%) | ||
| Annual report for 2025 | 2026-04-24 | 0.04 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-04-23 | 0.03 (-25.00%) | ||
| Third quarter earnings results for 2025 | 2025-11-28 | 0.04 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-08-28 | 0.04 (+0.00%) | ||
| General meeting for 2025 | 2025-06-25 16:00 | 0.05 (-10.00%) | ||
| First quarter earnings results for 2025 | 2025-05-29 | 0.06 (+0.00%) |
Show
Entries
Kane Biotech Inc Frequently Asked Questions
What is Kane Biotech Inc(TSXV:KNE)'s stock price today?
The current price of TSXV:KNE is C$0.03. The 52 week high of TSXV:KNE is C$0.05 and 52 week low is C$0.02.
When is next earnings date of Kane Biotech Inc(TSXV:KNE)?
The next earnings date of Kane Biotech Inc(TSXV:KNE) is 2026-08-28 Est..
Does Kane Biotech Inc(TSXV:KNE) pay dividends? If so, how much?
Kane Biotech Inc(TSXV:KNE) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Kane Biotech Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers